Global Oncology Companion Diagnostic Market 2022 by Company, Regions, Type and Application, Forecast to 2028
Page: 102
Published Date: 15 Jan 2022
Category: Medical Devices & Consumables
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The Oncology Companion Diagnostic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Oncology Companion Diagnostic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Oncology Companion Diagnostic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Polymerase Chain Reaction (PCR) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Oncology Companion Diagnostic include Agilent Technologies, Inc., Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Oncology Companion Diagnostic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
Market segment by Application, can be divided into
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
Market segment by players, this report covers
Agilent Technologies, Inc.
Illumina, Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Oncology Companion Diagnostic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Oncology Companion Diagnostic, with revenue, gross margin and global market share of Oncology Companion Diagnostic from 2019 to 2022.
Chapter 3, the Oncology Companion Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Oncology Companion Diagnostic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Oncology Companion Diagnostic research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Oncology Companion Diagnostic
1.2 Classification of Oncology Companion Diagnostic by Type
1.2.1 Overview: Global Oncology Companion Diagnostic Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Oncology Companion Diagnostic Revenue Market Share by Type in 2021
1.2.3 Polymerase Chain Reaction (PCR)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Immunohistochemistry (IHC)
1.2.6 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
1.2.7 Others
1.3 Global Oncology Companion Diagnostic Market by Application
1.3.1 Overview: Global Oncology Companion Diagnostic Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pathology/Diagnostic Laboratory
1.3.4 Academic Medical Center
1.4 Global Oncology Companion Diagnostic Market Size & Forecast
1.5 Global Oncology Companion Diagnostic Market Size and Forecast by Region
1.5.1 Global Oncology Companion Diagnostic Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Oncology Companion Diagnostic Market Size by Region, (2017-2022)
1.5.3 North America Oncology Companion Diagnostic Market Size and Prospect (2017-2028)
1.5.4 Europe Oncology Companion Diagnostic Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Oncology Companion Diagnostic Market Size and Prospect (2017-2028)
1.5.6 South America Oncology Companion Diagnostic Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Oncology Companion Diagnostic Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Oncology Companion Diagnostic Market Drivers
1.6.2 Oncology Companion Diagnostic Market Restraints
1.6.3 Oncology Companion Diagnostic Trends Analysis
2.1 Agilent Technologies, Inc.
2.1.1 Agilent Technologies, Inc. Details
2.1.2 Agilent Technologies, Inc. Major Business
2.1.3 Agilent Technologies, Inc. Oncology Companion Diagnostic Product and Solutions
2.1.4 Agilent Technologies, Inc. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Agilent Technologies, Inc. Recent Developments and Future Plans
2.2 Illumina, Inc.
2.2.1 Illumina, Inc. Details
2.2.2 Illumina, Inc. Major Business
2.2.3 Illumina, Inc. Oncology Companion Diagnostic Product and Solutions
2.2.4 Illumina, Inc. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Illumina, Inc. Recent Developments and Future Plans
2.3 Qiagen N.V.
2.3.1 Qiagen N.V. Details
2.3.2 Qiagen N.V. Major Business
2.3.3 Qiagen N.V. Oncology Companion Diagnostic Product and Solutions
2.3.4 Qiagen N.V. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Qiagen N.V. Recent Developments and Future Plans
2.4 Thermo Fisher Scientific Inc.
2.4.1 Thermo Fisher Scientific Inc. Details
2.4.2 Thermo Fisher Scientific Inc. Major Business
2.4.3 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Product and Solutions
2.4.4 Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.6 ARUP Laboratories
2.6.1 ARUP Laboratories Details
2.6.2 ARUP Laboratories Major Business
2.6.3 ARUP Laboratories Oncology Companion Diagnostic Product and Solutions
2.6.4 ARUP Laboratories Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 ARUP Laboratories Recent Developments and Future Plans
2.7 Abbott
2.7.1 Abbott Details
2.7.2 Abbott Major Business
2.7.3 Abbott Oncology Companion Diagnostic Product and Solutions
2.7.4 Abbott Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Abbott Recent Developments and Future Plans
2.8 Myriad Genetics, Inc.
2.8.1 Myriad Genetics, Inc. Details
2.8.2 Myriad Genetics, Inc. Major Business
2.8.3 Myriad Genetics, Inc. Oncology Companion Diagnostic Product and Solutions
2.8.4 Myriad Genetics, Inc. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Myriad Genetics, Inc. Recent Developments and Future Plans
2.9 bioMérieux SA
2.9.1 bioMérieux SA Details
2.9.2 bioMérieux SA Major Business
2.9.3 bioMérieux SA Oncology Companion Diagnostic Product and Solutions
2.9.4 bioMérieux SA Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 bioMérieux SA Recent Developments and Future Plans
2.10 Invivoscribe, Inc.
2.10.1 Invivoscribe, Inc. Details
2.10.2 Invivoscribe, Inc. Major Business
2.10.3 Invivoscribe, Inc. Oncology Companion Diagnostic Product and Solutions
2.10.4 Invivoscribe, Inc. Oncology Companion Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Invivoscribe, Inc. Recent Developments and Future Plans
3.1 Global Oncology Companion Diagnostic Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Oncology Companion Diagnostic Players Market Share in 2021
3.2.2 Top 10 Oncology Companion Diagnostic Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Oncology Companion Diagnostic Players Head Office, Products and Services Provided
3.4 Oncology Companion Diagnostic Mergers & Acquisitions
3.5 Oncology Companion Diagnostic New Entrants and Expansion Plans
4.1 Global Oncology Companion Diagnostic Revenue and Market Share by Type (2017-2022)
4.2 Global Oncology Companion Diagnostic Market Forecast by Type (2023-2028)
5.1 Global Oncology Companion Diagnostic Revenue Market Share by Application (2017-2022)
5.2 Global Oncology Companion Diagnostic Market Forecast by Application (2023-2028)
6.1 North America Oncology Companion Diagnostic Revenue by Type (2017-2028)
6.2 North America Oncology Companion Diagnostic Revenue by Application (2017-2028)
6.3 North America Oncology Companion Diagnostic Market Size by Country
6.3.1 North America Oncology Companion Diagnostic Revenue by Country (2017-2028)
6.3.2 United States Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
6.3.3 Canada Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
6.3.4 Mexico Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
7.1 Europe Oncology Companion Diagnostic Revenue by Type (2017-2028)
7.2 Europe Oncology Companion Diagnostic Revenue by Application (2017-2028)
7.3 Europe Oncology Companion Diagnostic Market Size by Country
7.3.1 Europe Oncology Companion Diagnostic Revenue by Country (2017-2028)
7.3.2 Germany Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
7.3.3 France Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
7.3.5 Russia Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
7.3.6 Italy Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.1 Asia-Pacific Oncology Companion Diagnostic Revenue by Type (2017-2028)
8.2 Asia-Pacific Oncology Companion Diagnostic Revenue by Application (2017-2028)
8.3 Asia-Pacific Oncology Companion Diagnostic Market Size by Region
8.3.1 Asia-Pacific Oncology Companion Diagnostic Revenue by Region (2017-2028)
8.3.2 China Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.3.3 Japan Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.3.4 South Korea Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.3.5 India Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
8.3.7 Australia Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
9.1 South America Oncology Companion Diagnostic Revenue by Type (2017-2028)
9.2 South America Oncology Companion Diagnostic Revenue by Application (2017-2028)
9.3 South America Oncology Companion Diagnostic Market Size by Country
9.3.1 South America Oncology Companion Diagnostic Revenue by Country (2017-2028)
9.3.2 Brazil Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
9.3.3 Argentina Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
10.1 Middle East & Africa Oncology Companion Diagnostic Revenue by Type (2017-2028)
10.2 Middle East & Africa Oncology Companion Diagnostic Revenue by Application (2017-2028)
10.3 Middle East & Africa Oncology Companion Diagnostic Market Size by Country
10.3.1 Middle East & Africa Oncology Companion Diagnostic Revenue by Country (2017-2028)
10.3.2 Turkey Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
10.3.4 UAE Oncology Companion Diagnostic Market Size and Forecast (2017-2028)
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Oncology Companion Diagnostic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Oncology Companion Diagnostic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Oncology Companion Diagnostic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Oncology Companion Diagnostic Revenue (USD Million) by Region (2017-2022)
Table 5. Global Oncology Companion Diagnostic Revenue Market Share by Region (2023-2028)
Table 6. Agilent Technologies, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Agilent Technologies, Inc. Major Business
Table 8. Agilent Technologies, Inc. Oncology Companion Diagnostic Product and Solutions
Table 9. Agilent Technologies, Inc. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Illumina, Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Illumina, Inc. Major Business
Table 12. Illumina, Inc. Oncology Companion Diagnostic Product and Solutions
Table 13. Illumina, Inc. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Qiagen N.V. Corporate Information, Head Office, and Major Competitors
Table 15. Qiagen N.V. Major Business
Table 16. Qiagen N.V. Oncology Companion Diagnostic Product and Solutions
Table 17. Qiagen N.V. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Thermo Fisher Scientific Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Thermo Fisher Scientific Inc. Major Business
Table 20. Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Product and Solutions
Table 21. Thermo Fisher Scientific Inc. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann-La Roche Ltd. Major Business
Table 24. F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Product and Solutions
Table 25. F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. ARUP Laboratories Corporate Information, Head Office, and Major Competitors
Table 27. ARUP Laboratories Major Business
Table 28. ARUP Laboratories Oncology Companion Diagnostic Product and Solutions
Table 29. ARUP Laboratories Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Abbott Corporate Information, Head Office, and Major Competitors
Table 31. Abbott Major Business
Table 32. Abbott Oncology Companion Diagnostic Product and Solutions
Table 33. Abbott Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Myriad Genetics, Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Myriad Genetics, Inc. Major Business
Table 36. Myriad Genetics, Inc. Oncology Companion Diagnostic Product and Solutions
Table 37. Myriad Genetics, Inc. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. bioMérieux SA Corporate Information, Head Office, and Major Competitors
Table 39. bioMérieux SA Major Business
Table 40. bioMérieux SA Oncology Companion Diagnostic Product and Solutions
Table 41. bioMérieux SA Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Invivoscribe, Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Invivoscribe, Inc. Major Business
Table 44. Invivoscribe, Inc. Oncology Companion Diagnostic Product and Solutions
Table 45. Invivoscribe, Inc. Oncology Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Oncology Companion Diagnostic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Oncology Companion Diagnostic Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Oncology Companion Diagnostic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Oncology Companion Diagnostic Players Head Office, Products and Services Provided
Table 50. Oncology Companion Diagnostic Mergers & Acquisitions in the Past Five Years
Table 51. Oncology Companion Diagnostic New Entrants and Expansion Plans
Table 52. Global Oncology Companion Diagnostic Revenue (USD Million) by Type (2017-2022)
Table 53. Global Oncology Companion Diagnostic Revenue Share by Type (2017-2022)
Table 54. Global Oncology Companion Diagnostic Revenue Forecast by Type (2023-2028)
Table 55. Global Oncology Companion Diagnostic Revenue by Application (2017-2022)
Table 56. Global Oncology Companion Diagnostic Revenue Forecast by Application (2023-2028)
Table 57. North America Oncology Companion Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Oncology Companion Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Oncology Companion Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Oncology Companion Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Oncology Companion Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Oncology Companion Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Oncology Companion Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Oncology Companion Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Oncology Companion Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Oncology Companion Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Oncology Companion Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Oncology Companion Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Oncology Companion Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Oncology Companion Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Oncology Companion Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Oncology Companion Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Oncology Companion Diagnostic Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Oncology Companion Diagnostic Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Oncology Companion Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Oncology Companion Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Oncology Companion Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Oncology Companion Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Oncology Companion Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Oncology Companion Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Oncology Companion Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Oncology Companion Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Oncology Companion Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Oncology Companion Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Oncology Companion Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Oncology Companion Diagnostic Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Oncology Companion Diagnostic Picture
Figure 2. Global Oncology Companion Diagnostic Revenue Market Share by Type in 2021
Figure 3. Polymerase Chain Reaction (PCR)
Figure 4. Next-Generation Sequencing (NGS)
Figure 5. Immunohistochemistry (IHC)
Figure 6. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Figure 7. Others
Figure 8. Oncology Companion Diagnostic Revenue Market Share by Application in 2021
Figure 9. Hospital Picture
Figure 10. Pathology/Diagnostic Laboratory Picture
Figure 11. Academic Medical Center Picture
Figure 12. Global Oncology Companion Diagnostic Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Oncology Companion Diagnostic Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Oncology Companion Diagnostic Revenue Market Share by Region (2017-2028)
Figure 15. Global Oncology Companion Diagnostic Revenue Market Share by Region in 2021
Figure 16. North America Oncology Companion Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Oncology Companion Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Oncology Companion Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Oncology Companion Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Oncology Companion Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Oncology Companion Diagnostic Market Drivers
Figure 22. Oncology Companion Diagnostic Market Restraints
Figure 23. Oncology Companion Diagnostic Market Trends
Figure 24. Agilent Technologies, Inc. Recent Developments and Future Plans
Figure 25. Illumina, Inc. Recent Developments and Future Plans
Figure 26. Qiagen N.V. Recent Developments and Future Plans
Figure 27. Thermo Fisher Scientific Inc. Recent Developments and Future Plans
Figure 28. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 29. ARUP Laboratories Recent Developments and Future Plans
Figure 30. Abbott Recent Developments and Future Plans
Figure 31. Myriad Genetics, Inc. Recent Developments and Future Plans
Figure 32. bioMérieux SA Recent Developments and Future Plans
Figure 33. Invivoscribe, Inc. Recent Developments and Future Plans
Figure 34. Global Oncology Companion Diagnostic Revenue Share by Players in 2021
Figure 35. Oncology Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Oncology Companion Diagnostic Revenue Market Share in 2021
Figure 37. Global Top 10 Players Oncology Companion Diagnostic Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Oncology Companion Diagnostic Revenue Share by Type in 2021
Figure 40. Global Oncology Companion Diagnostic Market Share Forecast by Type (2023-2028)
Figure 41. Global Oncology Companion Diagnostic Revenue Share by Application in 2021
Figure 42. Global Oncology Companion Diagnostic Market Share Forecast by Application (2023-2028)
Figure 43. North America Oncology Companion Diagnostic Sales Market Share by Type (2017-2028)
Figure 44. North America Oncology Companion Diagnostic Sales Market Share by Application (2017-2028)
Figure 45. North America Oncology Companion Diagnostic Revenue Market Share by Country (2017-2028)
Figure 46. United States Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Oncology Companion Diagnostic Sales Market Share by Type (2017-2028)
Figure 50. Europe Oncology Companion Diagnostic Sales Market Share by Application (2017-2028)
Figure 51. Europe Oncology Companion Diagnostic Revenue Market Share by Country (2017-2028)
Figure 52. Germany Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Oncology Companion Diagnostic Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific Oncology Companion Diagnostic Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Oncology Companion Diagnostic Revenue Market Share by Region (2017-2028)
Figure 60. China Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Oncology Companion Diagnostic Sales Market Share by Type (2017-2028)
Figure 67. South America Oncology Companion Diagnostic Sales Market Share by Application (2017-2028)
Figure 68. South America Oncology Companion Diagnostic Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Oncology Companion Diagnostic Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa Oncology Companion Diagnostic Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Oncology Companion Diagnostic Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Oncology Companion Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Agilent Technologies, Inc. Illumina, Inc. Qiagen N.V. Thermo Fisher Scientific Inc. F. Hoffmann-La Roche Ltd. ARUP Laboratories Abbott Myriad Genetics, Inc. bioMérieux SA Invivoscribe, Inc.
Related Reports
29 Jan 2021
Medical Devices & Consumables
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
